Pfizer Signs an Option and License Agreement with Voyager to Develop and Commercialize Gene Therapies for Neurologic and Cardiovascular Diseases
Shots: Voyager to receive $30M up front, $20M as exercise fees for 2 options (exercisable within 12mos.) & ~$580M as development, regulatory & commercial milestones related to licensed products including 2 undisclosed Pfizer’s transgenes along with royalties based on sales of products including licensed capsids Pfizer gets the right to assess novel capsids for CNS […]